What Would You Sacrifice For Lower Premiums? For Younger Consumers The Answer Is Privacy
If it ends with them saving money, the younger consumers were happy to let insurers trawl through their digital data. As the ages went up, people were less inclined to be alright with the tactic.
Bloomberg:
Most Under-35s OK With Insurers Digital Spying If It Cuts Prices
The majority of people between 18 and 34 would be willing to let insurance companies dig through their digital data from social media to health devices if it meant lowering their premiums, a survey shows. In the younger group, 62 percent said they’d be happy for insurers to use third-party data from the likes of Facebook, fitness apps and smart-home devices to lower prices, according to a survey of more than 8,000 consumers globally by Salesforce.com Inc.’s MuleSoft Inc. That drops to 44 percent when the older generations are included. (Edde, 6/19)
In other national health care news —
The New York Times:
It Was Supposed To Be An Unbiased Study Of Drinking. They Wanted To Call It ‘Cheers.’
The director of the nation’s top health research agency pulled the plug on a study of alcohol’s health effects without hesitation on Friday, saying a Harvard scientist and some of his agency’s own staff had crossed “so many lines” in pursuit of alcohol industry funding that “people were frankly shocked.” A 165-page internal investigation prepared for Dr. Francis Collins, director of the National Institutes of Health, concluded that Kenneth J. Mukamal, the lead investigator of the trial, was in close, frequent contact with beer and liquor executives while designing the study. (Rabin, 6/18)
The Associated Press:
US Could Back 1st Pot-Derived Medicine, And Some Are Worried
A British pharmaceutical company is getting closer to a decision on whether the U.S government will approve the first prescription drug derived from the marijuana plant, but parents who for years have used cannabis to treat severe forms of epilepsy in their children are feeling more cautious than celebratory. The U.S. Food and Drug Administration is expected to decide by the end of the month whether to approve GW Pharmaceuticals' Epidiolex. It's a purified form of cannabidiol — a component of cannabis that doesn't get users high — to treat Dravet and Lennox-Gastaut syndromes in kids. Both forms of epilepsy are rare. (Foody and Banda, 6/19)
Stat:
Boundary-Breaking Neurologist Treats Patients Other Doctors Give Up On
Her neurology work at Massachusetts General Hospital involves plenty of gadgetry — she heads up the deep brain stimulation unit, and sometimes uses electroconvulsive therapy to help patients with depression or mania — but these days, that’s not the kind of tinkering that’s at the front of her mind. Instead, she has been toying with the boundaries of illness itself. She likes seeing patients other doctors have given up on. Many have faced questions about whether they’re really as sick as they say. For all of them, getting the proper treatment — pills or infusions or electrical currents — depends on a kind of collaboration with [Dr. Alice] Flaherty, a workshop in which motivations are re-examined, stories reshaped, turns of phrase redefined. (Boodman, 6/19)
The New York Times:
A Third Of Children Use Alternative Medicines
A third of children under 19 are regular users of dietary supplements or alternative medicines. Using data from a large national health survey, researchers found that multivitamins were the most common supplements, followed by vitamin C, omega-3 fatty acids, vitamin D and melatonin. Three percent of male teenagers took bodybuilding supplements, and so did 1.3 percent of teenage girls. Omega-3 fatty acids were used by 2.3 percent of children under 19. Melatonin and other sleep aids were used by 1.6 percent of adolescents and by 1.2 percent of children under 5. (Bakalar, 6/18)